Abstract
Over the last decades estrogen has been recognized to be involved in normal brain function due to its neurothrophic and neuroprotective effects. Estrogen is intimately associated with neuronal survival, mitochondrial function, neuroinflammation and cognition through genomic as well as non-genomic pathways. It is also known that the neuroprotective actions mediated by estrogens are interlinked with the insulin-like growth factor-1 (IGF-1) signaling pathway. This review is mainly devoted to explore the physiological and pathophysiological effects of estrogen and its signaling pathways in the brain. The molecular mechanisms underlying these effects are also debated. Finally, we discuss the potential neuroprotection afforded by estrogens in Alzheimers disease pathophysiology focusing in the “window of opportunity” for the initiation of estrogen therapy as a critical factor in the fight against neurodegeneration.
Keywords: Alzheimer's disease, estrogen, IGF-1, mitochondria, neuroinflammation, neuroprotection
Current Aging Science
Title: Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Volume: 3 Issue: 2
Author(s): Sonia C. Correia, Renato X. Santos, Susana Cardoso, Cristina Carvalho, Maria S. Santos, Catarina R. Oliveira and Paula I. Moreira
Affiliation:
Keywords: Alzheimer's disease, estrogen, IGF-1, mitochondria, neuroinflammation, neuroprotection
Abstract: Over the last decades estrogen has been recognized to be involved in normal brain function due to its neurothrophic and neuroprotective effects. Estrogen is intimately associated with neuronal survival, mitochondrial function, neuroinflammation and cognition through genomic as well as non-genomic pathways. It is also known that the neuroprotective actions mediated by estrogens are interlinked with the insulin-like growth factor-1 (IGF-1) signaling pathway. This review is mainly devoted to explore the physiological and pathophysiological effects of estrogen and its signaling pathways in the brain. The molecular mechanisms underlying these effects are also debated. Finally, we discuss the potential neuroprotection afforded by estrogens in Alzheimers disease pathophysiology focusing in the “window of opportunity” for the initiation of estrogen therapy as a critical factor in the fight against neurodegeneration.
Export Options
About this article
Cite this article as:
C. Correia Sonia, X. Santos Renato, Cardoso Susana, Carvalho Cristina, S. Santos Maria, R. Oliveira Catarina and I. Moreira Paula, Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?, Current Aging Science 2010; 3 (2) . https://dx.doi.org/10.2174/1874609811003020113
DOI https://dx.doi.org/10.2174/1874609811003020113 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Physiological Functions of Presenilins; Beyond γ-Secretase
Current Pharmaceutical Biotechnology Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry The Role of Tau Phosphorylation in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets The Action of Prostaglandins on Ion Channels
Current Neuropharmacology Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Prion Disease: Chemotherapeutic Strategies
Infectious Disorders - Drug Targets NMDA Receptors in Glial Cells: Pending Questions
Current Neuropharmacology Nutritional Aspects Relating to the Developmental Origins of Health and Disease
Current Women`s Health Reviews Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry Lactoferrin Derived Peptides: Mechanisms of Action and their Perspectives as Antimicrobial and Antitumoral Agents
Mini-Reviews in Medicinal Chemistry Antiangiogenic Function of Antithrombin is Dependent on its Conformational Variation: Implication for Other Serpins
Protein & Peptide Letters Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design subject Index To Volume 2
Current Molecular Medicine